Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE)

Trial Profile

Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs AR 101 (Primary)
  • Indications Peanut hypersensitivity
  • Focus Registrational; Therapeutic Use
  • Acronyms PALISADE
  • Sponsors Aimmune Therapeutics
  • Most Recent Events

    • 08 Aug 2017 According to an Aimmune Therapeutics media release, this trial is expected to complete around the end of 2017 and topline results are expected in the first quarter of 2018
    • 20 Jun 2017 Findings from pre-randomization, preliminary clinical data collected from the European screening population (n = 166) were presented at the 2017 European Academy of Allergy and Clinical Immunology (EAACI) Congress according to an Aimmune Therapeutics media release.
    • 20 Jun 2017 Results from a preliminary dataset of 166 patients published in an Aimmune Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top